GlassScriptPhysician profile
Nolan J Mayer
NPI 1457364655
$8,781.01
in general payments reported to CMS, 2019-2025
39 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $930 · 2021: $1,351 · 2022: $1,284 · 2023: $1,362 · 2024: $965 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,233.92 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $940.46 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $886.12 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $844.71 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $573.34 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $572.31 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $470.42 | 2019-2024 | Lokelma, Farxiga, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $437.26 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.77 | 2021-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $275.21 | 2022-2025 | Amvuttra, Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $212.77 | 2024 | Arcalyst |
| Pfizer INC. | $210.52 | 2019-2025 | |
| Amarin Pharma, INC. | $190.57 | 2019 | |
| Esperion Therapeutics, INC. | $165.71 | 2020-2025 | Nexletol |
| Abbott Laboratories | $148.00 | 2019-2024 | Aveir |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.